Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Current Assets of $172.2 million for Q1 2026, up 82.85% year-over-year from $94.2 million in Q1 2025, and down 4.4% quarter-over-quarter from $180.1 million in Q4 2025.
Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Current Assets for 7 consecutive years, with $172.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 82.85% year-over-year to $172.2 million; the TTM figure through Mar 2026 stood at $172.2 million (up 82.85% YoY), while the FY2025 annual figure was $180.1 million, up 82.94% from the prior year.
- Current Assets fell to $172.2 million in Q1 2026 per IKT's latest filing, from $180.1 million in the prior quarter.
- Across five years, Current Assets topped out at $180.1 million in Q4 2025 and bottomed at $4.2 million in Q3 2024.
- Historically, Current Assets has averaged $56.5 million across 5 years, with a median of $27.8 million in 2022.
- Annual changes were most pronounced in 2024 — Current Assets slumped 76.13% — and 2025, when it soared 1774.34%.
- Inhibikase Therapeutics' Current Assets stood at $24.4 million in 2022, then tumbled by 41.69% to $14.2 million in 2023, then soared by 592.78% to $98.5 million in 2024, then jumped by 82.94% to $180.1 million in 2025, then fell by 4.4% to $172.2 million in 2026.
- Business Quant data shows IKT's Current Assets at $172.2 million in Q1 2026, $180.1 million in Q4 2025, and $78.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 162.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.34 Mn |
| Mar 31, 2026 | 172.18 Mn |
| Dec 31, 2025 | 180.11 Mn |
| Sep 30, 2025 | 78.54 Mn |
| Jun 30, 2025 | 88.79 Mn |
| Mar 31, 2025 | 94.16 Mn |
| Dec 31, 2024 | 98.45 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 8.60 Mn |
| Mar 31, 2024 | 10.81 Mn |
| Dec 31, 2023 | 14.21 Mn |
| Sep 30, 2023 | 17.55 Mn |
| Jun 30, 2023 | 21.98 Mn |
| Mar 31, 2023 | 27.63 Mn |
| Dec 31, 2022 | 24.37 Mn |
| Sep 30, 2022 | 27.99 Mn |
| Jun 30, 2022 | 33.95 Mn |
| Dec 31, 2021 | 42.47 Mn |
| Mar 31, 2021 | 11.87 Mn |
| Dec 31, 2020 | 14.78 Mn |